Corvus Pharmaceuticals Crecimiento futuro
Future controles de criterios 0/6
Se prevé que los beneficios de Corvus Pharmaceuticals disminuyan a un ritmo anual de 3.9%, mientras que sus ingresos anuales crecerán a un ritmo de 75.9% por año. Se espera que el BPA crezca en un 8.6% al año.
Información clave
-3.9%
Tasa de crecimiento de los beneficios
8.6%
Tasa de crecimiento del BPA
Crecimiento de los beneficios de Biotechs | 30.0% |
Tasa de crecimiento de los ingresos | 75.9% |
Rentabilidad financiera futura | n/a |
Cobertura de analistas | Low |
Última actualización | 16 Aug 2024 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Corvus Pharmaceuticals: Soquelitinib's High Stakes In PTCL Therapy
Sep 02Will Corvus Pharmaceuticals (NASDAQ:CRVS) Spend Its Cash Wisely?
Mar 06Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation
Oct 23Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Invest In Growth?
May 16Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation
Dec 05Corvus' partner Angel Pharma gets nod to start phase 1/1b trial of cancer therapy in China
Sep 26We're Keeping An Eye On Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Rate
Aug 14Companies Like Corvus Pharmaceuticals (NASDAQ:CRVS) Are In A Position To Invest In Growth
Apr 05We're Hopeful That Corvus Pharmaceuticals (NASDAQ:CRVS) Will Use Its Cash Wisely
Dec 15Checking In On Corvus Pharmaceuticals
Dec 10Corvus: Surging On AstraZeneca CD73 Success With Key Data Readout Looming
Sep 22We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business Growth
Aug 26Corvus Pharmaceuticals initiated buy at Cantor with a Street-high target
May 27Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Deliver On Growth Plans?
May 08The Co-Founder of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), Richard Miller, Just Bought 8.5% More Shares
Feb 19Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation
Feb 07Here's What Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) Shareholder Ownership Structure Looks Like
Dec 16Corvus Pharmaceuticals EPS misses by $0.06
Oct 29Previsiones de crecimiento de beneficios e ingresos
Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
---|---|---|---|---|---|
12/31/2026 | 6 | -50 | -40 | N/A | 5 |
12/31/2025 | N/A | -39 | -29 | N/A | 5 |
12/31/2024 | N/A | -25 | -22 | N/A | 5 |
6/30/2024 | N/A | -23 | -21 | -21 | N/A |
3/31/2024 | N/A | -25 | -21 | -21 | N/A |
12/31/2023 | N/A | -27 | -24 | -24 | N/A |
9/30/2023 | N/A | -30 | -26 | -26 | N/A |
6/30/2023 | N/A | -39 | -28 | -28 | N/A |
3/31/2023 | N/A | -41 | -29 | -29 | N/A |
12/31/2022 | N/A | -41 | -27 | -27 | N/A |
9/30/2022 | N/A | -41 | -27 | -26 | N/A |
6/30/2022 | N/A | -37 | -28 | -28 | N/A |
3/31/2022 | N/A | -40 | -34 | -34 | N/A |
12/31/2021 | N/A | -43 | -37 | -37 | N/A |
9/30/2021 | N/A | -7 | -38 | -38 | N/A |
6/30/2021 | N/A | -6 | -37 | -37 | N/A |
3/31/2021 | N/A | -5 | -34 | -34 | N/A |
12/31/2020 | N/A | -6 | -35 | -35 | N/A |
9/30/2020 | N/A | -44 | -35 | -35 | N/A |
6/30/2020 | N/A | -46 | -38 | -38 | N/A |
3/31/2020 | N/A | -48 | -38 | -38 | N/A |
12/31/2019 | N/A | -47 | -37 | -37 | N/A |
9/30/2019 | N/A | -46 | -37 | -37 | N/A |
6/30/2019 | N/A | -46 | -38 | -37 | N/A |
3/31/2019 | N/A | -44 | -39 | -39 | N/A |
12/31/2018 | N/A | -47 | -41 | -41 | N/A |
9/30/2018 | N/A | -48 | -44 | -44 | N/A |
6/30/2018 | N/A | -51 | -44 | -44 | N/A |
3/31/2018 | N/A | -54 | N/A | -45 | N/A |
12/31/2017 | N/A | -56 | N/A | -46 | N/A |
9/30/2017 | N/A | -55 | N/A | -45 | N/A |
6/30/2017 | N/A | -52 | N/A | -41 | N/A |
3/31/2017 | N/A | -46 | N/A | -35 | N/A |
12/31/2016 | N/A | -36 | N/A | -28 | N/A |
9/30/2016 | N/A | -31 | N/A | -22 | N/A |
6/30/2016 | N/A | -24 | N/A | -19 | N/A |
3/31/2016 | N/A | -36 | N/A | -15 | N/A |
12/31/2015 | N/A | -31 | N/A | -11 | N/A |
9/30/2015 | N/A | -25 | N/A | -7 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que CRVS siga sin ser rentable en los próximos 3 años.
Beneficios vs. Mercado: Se prevé que CRVS siga sin ser rentable en los próximos 3 años.
Beneficios de alto crecimiento: Se prevé que CRVS siga sin ser rentable en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que CRVS no tenga ingresos el año que viene.
Ingresos de alto crecimiento: Se prevé que CRVS no tenga ingresos el año que viene.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de CRVS se prevé que sea elevada dentro de 3 años.